As the efficacy of BRAF inhibitor plus MEK inhibitor (BRAFi/MEKi) is limited in patients with elevated LDH levels [3,4], nivo/ipi combination therapy could be a first-line immunotherapy for BRAF-mutant advanced melanoma with a high tumor burden. The gene discussed is BRAF; the disease is melanoma.